Matching geography Reports matching your search in: Join Alert Me now! Receive bi-weekly email alerts on new market research Sign up today!
|
Radiopharmaceuticals: market research reports
Radiopharmaceuticals are radioactive pharmaceuticals used in medical imaging as tracers for the identification and diagnosis of many illnesses. Nuclear medicine modalities – SPECT and PET – use radiopharmaceuticals to generate diagnostic images. These nuclear pharmaceuticals combine physiologically active carriers with a radioisotope. It is possible to manufacture chemical or biological carriers which migrate to a particular part of the human body. For example, iodine concentrates in the thyroid gland. The radioisotope attached to these compounds emits radiation so that the relevant organ and its functioning can be imaged.
A radiopharmaceutical, which involves the use of radioactive agents in vivo to diagnose or treat specific diseases and conditions, generally consists of two components which determine its characteristics and clinical potential. The most common diagnostic molecular imaging agents use radioactive isotopes as the signal source. A radioactive isotope -- a radioisotope or radionuclide -- is a natural or artificially created isotope with an unstable nucleus that decays -- emitting alpha or beta particles, positrons, or gamma rays. As it decays, it loses mass and energy, until a stable isotope develops. For most elements, both stable and radioactive isotopes are known.
Examples of radioisotopes commonly combined with pharmaceutically-active molecules to form radiopharmaceuticals include technetium-99m, gallium-67, Iodine-123, Iodine-13, Thallium-201, Fluorine-18, and Indium-111.
A number of SPECT radiopharmaceuticals incorporate antibody and peptide formulations that can be targeted to specific tissue receptors, allowing one to discriminate healthy from diseased tissue with a high confidence level. However, the more specific the targeting agent is, the more difficult it is to interpret its position anatomically, since there are fewer landmarks.
Radiopharmaceuticals market research reports and industry analysis
|
|
$4,650.00
|
Advances in Molecular Imaging: A market coming of age
4/9/2013 | published by: Espicom Healthcare Intelligence
... to peg back the sector’s growth. But since 2010 things have improved; pressure in the US market has eased and growth has come from increasing demand in emerging markets such as India and China. The ...
|
read more...
|
$1,740.00
|
|
|
$4,650.00
|
Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017
4/3/2013 | published by: MarketsandMarkets
... (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in ...
|
read more...
|
$4,650.00
|
|
|
$3,995.00
|
Imaging Agents
2/1/2012 | published by: Global Industry Analysts
... US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. ...
|
read more...
|
$4,500.00
|
Radiopharmaceuticals
10/1/2011 | published by: Global Industry Analysts
... 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare ...
|
read more...
|
$4,500.00
|
|
|
$4,650.00
|
Imaging Agents
2/1/2011 | published by: Global Industry Analysts
... US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. ...
|
read more...
|
$4,500.00
|
|
|
$795.00
|
Advances in SPECT Imaging (Technical Insights)
12/31/2010 | published by: Frost & Sullivan
... restraints, various technology innovations and analysis of stakeholders, assessment of industry initiatives with Analytical Hierarchy Process(AHP) based competitive bench marking of imaging modalities for cardiac imaging. Finally a list of patents pertaining to SPECT instrumentation ...
|
read more...
|
$6,500.00
|
US Markets for Contrast Agents and Radiopharmaceuticals 2011
11/24/2010 | published by: Millennium Research Group
... care costs. This began with cost-containment measures spurred by rising diagnostic imaging procedures prior to reimbursement cuts under the 2005 Deficit Reduction Act. Many insurers are mandating the preauthorization of imaging scans before coverage can ...
|
read more...
|
$4,337.00
|
Emerging Technology Developments in Hybrid Imaging (Technical Insights)
9/30/2010 | published by: Frost & Sullivan
... drivers, restraints and challenges, diffusion of innovations assessment which include application-wise and region-wise adoption potential of the various hybrid imaging modalities discussed, analysis of end user demands, opportunities and strategic recommendations. Finally a list of ...
|
read more...
|
$6,500.00
|
Medical Imaging Markets: Contrast Agents
11/1/2009 | published by: Kalorama Information
... in order. This bodes well for contrast media markets. Since our last round-up of the contrast media market, the economic environment in the world has changed. Although the recession may have caused hospitals, physician offices ...
|
read more...
|
$3,500.00
|
|
|
$795.00
|
|
|
$795.00
|
|
|
$495.00
|
|
|
$495.00
|
|
|
$495.00
|
|
|
$495.00
|
U.S. Radiopharmaceutical Agents Markets
6/3/2008 | published by: Frost & Sullivan
... eleven year period, from 2004 to 2014, with the base year being 2007. The research service provides a comprehensive analysis and forecasts for revenue by segment, demand analysis including data on procedure volumes, procedure types, ...
|
read more...
|
$8,500.00
|
Imaging Agents (Contrast Media, Radiopharmaceuticals)
5/1/2008 | published by: Global Industry Analysts
... the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 67 companies including many key and niche ...
|
read more...
|
$3,950.00
|
Medical Imaging Markets, Volume IV: Contrast Agents
2/1/2007 | published by: Kalorama Information
... growing marketplace in these agents. The introduction and now brisk ongoing development of contrast media for traditional radiography, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron-emission tomography (PET), and single-photon emission computed tomography (SPECT), ...
|
read more...
|
$1,995.00
|
|
|
$6,800.00
|
U.S. Radiopharmaceuticals Markets
5/1/2002 | published by: Frost & Sullivan
... prior to structural change. Commercial development of alpha-emitters, for example, will provide radiologists with better tools to target tumor cells and offer new opportunities for pharmaceutical firms. This research analyzes the U.S. markets for radiopharmaceuticals, ...
|
read more...
|
$3,950.00
|
|